- Travere pays Everest $112M upfront to grow rare kidney disease pipelineTravere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out…Endpoints · 1mo ago↗ source
- Legend Biotech shares first in vivo CAR-T data, its next act after CarvyktiLegend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field. Legend reported results Tuesday on 12 lymphoma patients from an investigator-init…Endpoints · 1mo ago↗ source
- #ASCO26: Celcuity plans another FDA filing after positive breast cancer readoutCelcuity said a combination regimen with its experimental drug gedatolisib doubled patients' likelihood of survival without disease progression or death in a late-stage breast cancer trial. Execu…